

**Amendments to the Claims**

1. (Canceled herein)
2. (Canceled herein)
3. (Canceled herein)
4. (Canceled herein)
5. (Canceled herein)
6. (Canceled herein)
7. (Canceled herein)
8. (Canceled herein)
9. (Canceled herein)
10. (Canceled herein)
11. (Canceled herein)

12. (New) A method of delivering a substance to microtubules, comprising exposing said microtubules to said substance, said substance being in a form selected from the group consisting of a fusion, a covalent coupling and a non-covalent association, of said substance with a protein, wherein said protein is a herpesviral VP22 protein, or is a portion or derivative thereof which has a microtubule binding function of VP22.

13. (New) A method of preparing a medicament for delivery of a substance to microtubules which comprises fusing, covalently coupling or non-covalently associating said substance for delivery with a herpesviral VP22 protein, or a portion or derivative thereof which has microtubule binding function of VP22, and then formulating the fused, covalently coupled, or non-covalently associated substance with a pharmaceutically acceptable excipient, thereby to form said medicament.

14. (New) The method of claim 13, wherein the medicament is a coupling product comprising both herpesviral VP22 and a substance to be delivered to microtubules.

15. (New) The method of claim 13, wherein the substance binds to microtubules.
16. (New) The method of claim 15, wherein the substance is taxol, or colchicine.